Multifunctional immature dental pulp stem cells and therapeutic applications
The present invention is directed to therapeutic multifunctional immature dental pulp stem cells (IDPSCs), and IDPSCs multi-lineage compositions. The invention is further directed to the use of IDPSCs and compositions to reduce the risk of and/or treat degenerative diseases or for other medicinal and aesthetic purposes.
1. A method of treating a disease or condition of ectodermal origin, wherein the disease or condition is selected from the group consisting of: a demyelinating disease, wherein the demyelinating disease attacks the central nervous system or the peripheral nervous system, and a spinal cord injury,
the method comprising systemically administering to a subject in need thereof a composition comprising a population of migratory immature dental pulp stem cells (IDPSCs) expressing CD73 (ecto-5′-nucleotidase), p53, and p75 in an amount sufficient to treat the disease or condition of ectodermal origin.
2. The method of claim 1 , wherein the demyelinating disease is selected from the group consisting of: Multiple sclerosis, idiopathic inflammatory demyelinating diseases, Vitamin B12 deficiency, central pontine myelinolysis, Tabes Dorsalis, transverse myelitis, Devic's disease, Progressive multifocal leukoencephalopathy, Optic neuritis, Leukodystrophies, Guillain-Barré syndrome, chronic inflammatory demyelinating polyneuropathy, Anti-MAG peripheral neuropathy, Charcot-Marie-Tooth Disease, and Copper deficiency.
3. The method of claim 1 , wherein the IDPSCs carry mesenchymal stem cell (MSC) markers.
4. The method of claim 3 , wherein the IDPSCs express CD105, CD73, and CD90 and lack expression of CD45, CD34, and HLA-DR.
5. The method of claim 4 , wherein the IDPSCs are plastic adherent cells.
6. The method of claim 3 , wherein the IDPSCs express CD29 (integrin beta 1).
7. The method of claim 6 , wherein the IDPSCs are plastic adherent cells.
8. The method of claim 3 , wherein the IDPSCs are plastic adherent cells.
9. The method of claim 1 , wherein the IDPSCs are plastic adherent cells.
10. The method of any one of claims 1 - 2 , and 3 - 7 , wherein administration of the IDPSCs is parenteral.
11. The method of claim 10 , wherein administration of the IDPSCs is intravenous.